Gilead Sciences, Inc. Submits Marketing Applications in the United States and European Union for Viread(R) (Tenofovir Disoproxil Fumarate) for the Treatment of Chronic Hepatitis B

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) and a Type II variation to the European Medicines Agency (EMEA) for marketing approval of Viread® (tenofovir disoproxil fumarate) for the treatment of chronic hepatitis B in adults. Viread is already approved in the United States and European Union for the treatment of HIV as part of combination antiretroviral therapy.